Comparative Pharmacology
Head-to-head clinical analysis: MYFED versus NAPHCON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYFED versus NAPHCON A.
MYFED vs NAPHCON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
Naphcon-A combines naphazoline, an alpha-adrenergic receptor agonist, and pheniramine, a histamine H1-receptor antagonist. Naphazoline constricts conjunctival blood vessels via alpha-adrenergic stimulation, reducing redness and edema. Pheniramine blocks histamine effects, alleviating itching and allergic reactions.
500 mg orally twice daily with meals.
1-2 drops instilled into the conjunctival sac every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
3-5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Naphazoline: ~2-3 hours; antazoline: ~3-4 hours. Clinical context: ocular administration, systemic absorption minimal.
Primarily renal (85-90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal excretion (5-10%).
Primarily renal excretion of unchanged drug and metabolites; naphazoline <10% unchanged, antazoline ~30% unchanged. Biliary/fecal elimination negligible.
Category C
Category C
Decongestant
Ophthalmic Antihistamine/Decongestant